This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ruilope, L. M Articles by Schiffrin, E. L Search for Related Content PubMed PubMed Citation Articles by Ruilope, L. M Articles by Schiffrin, E. L Social Bookmarking                         What's this?

Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?

Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain, Luis_M_Ruilope @teleline.es

Julian Segura

Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain

Ernesto L Schiffrin

Multidisciplinary Research Group on Hypertension, Clinical Research Institute, University of Montréal, Montréal, Quebec, Canada

Blockade of the effects of angiotensin II (Ang II) by using an angiotensin-converting enzyme (ACE) inhibitor has been proven to be of value in Type 1 diabetic nephropathy and in non-diabetic renal disease. Evidence in favour of Ang II blockade in Type 2 diabetic patients with renal damage is still lacking for ACE inhibitors (ACE-Is), while recent data indicate that angiotensin receptor blockers (ARBs) could be the drugs of choice in this situation. On the other hand, renal damage from the onset of disease is accompanied by a very significant increment in global cardiovascular risk. This fact, as well as that of simultaneous renal and cardiovascular protection, have to be considered for drug selection. In this sense, ACE-Is have been shown to be the drugs of choice when secondary cardiovascular prevention is required, while the evidence in primary prevention in hypertensive patients has been shown with losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. All these facts led to the conclusion that both ACE-Is and ARBs can be considered when both renal and cardiovascular protection are aimed for in Type 2 diabetic patients.

Key Words: ACE inhibition • angiotensin receptor antagonists • losartan • irbesartan • proteinuria • microalbuminuria • renal function • cardiovascular disease

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 2, 74-79 (2003)
DOI: 10.3317/jraas.2003.016


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Montalescot and J.-P. Collet Preserving cardiac function in the hypertensive patient: why renal parameters hold the key Eur. Heart J., December 2, 2005; 26(24): 2616 - 2622. [Abstract] [Full Text] [PDF]